ESMO 2023 Update – KEYNOTE-671: The First Perioperative Immunotherapy Clinical Trial in Non-Small Cell Lung Cancer Improving Overall Survival Author: Lei Deng, MD Assistant Professor/Medical Oncologist Thoracic, Head & Neck Medical Oncology
By Dr. Anam Kamal Ascension Providence Hospital TROPION-Lung01: A randomized, phase-3 study of datopotamab deruxtecan (Dato-DXd; DS-1062) versus docetaxel in previously treated advanced or metastatic non-small cell lung cancer (NSCLC) without actionable
More
ESMO 2023 Update – KEYNOTE-671: The First Perioperative Immunotherapy Clinical Trial in Non-Small Cell Lung Cancer Improving Overall Survival Author: Lei Deng, MD Assistant Professor/Medical Oncologist Thoracic, Head & Neck Medical Oncology
More
ESMO 2023 Update – MARIPOSA: Amivantamab + Lazertinib Improves Progression-Free Survival Compared to Osimertinib in EGFR-Mutated, Treatment-Naïve Non-Small Cell Lung Cancer Lei Deng, MD Assistant Professor/Medical Oncologist Thoracic, Head & Neck
More
ESMO 2023 Update – ALINA: Adjuvant Alectinib Improves Disease-Free Survival in Resected Early-Stage Non-Small Cell Lung Cancer Author: Lei Deng, MD Assistant Professor/Medical Oncologist Thoracic, Head & Neck Medical Oncology University of
More
LIBRETTO-431: Randomized phase III study of selpercatinib versus chemotherapy and pembrolizumab in RET fusion-positive advanced NSCLC Author: Dr. Anam Kamal Selpercatinib is a brain penetrant, a highly selective and potent inhibitor of RET signaling that
More
ESMO 2023 Update – CheckMate 77T: Another Phase 3 Trial of Perioperative Immunotherapy Improving Event-Free Survival for Resectable Stage II-III Non-Small Cell Lung Cancer Author: Lei Deng, MD Assistant Professor/Medical Oncologist Thoracic,
More